Back to News
Market Impact: 0.4
Connect Biopharma Reports Positive Phase 2 Rademikibart Data In Acute COPD
Source: Nasdaq
Healthcare & Biotech
Connect Biopharma reported positive preliminary topline results from its global Phase 2 Seabreeze STAT COPD trial of rademikibart. The study evaluated the drug as an add-on treatment for acute COPD exacerbations in adults with type 2 inflammation, providing a positive clinical-development catalyst for CNTB.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk
- AI Equity Research Tools for RIAs and Wealth Managers